WCLC 2025 - Posters & ePosters-P3.09.08 Tumor Treating Fields for Patients With Metastatic Non-Small Cell Lung Cancer: Real World First Experience

P3.09.08 Tumor Treating Fields for Patients With Metastatic Non-Small Cell Lung Cancer: Real World First Experience

Pdf Summary

This study reports the first real-world experience of using Tumor Treating Fields (TTFields) in patients with metastatic non-small cell lung cancer (mNSCLC) in the United States following FDA approval in October 2024. TTFields are frequency-specific alternating electric fields that disrupt cancer cell mitosis and may stimulate an antitumor immune response. Their efficacy, including overall survival benefit, was established in the phase III LUNAR trial.<br /><br />Data collected until March 7, 2025, included 91 patients prescribed TTFields after progression on or after platinum-based therapy. Of these, 62 patients (68%) initiated TTFields treatment. The median age was 66 years, with a slight predominance of females (55%). Most patients had adenocarcinoma histology (69%), followed by squamous cell carcinoma (26%). Concurrent systemic therapy was primarily immune checkpoint inhibitors (ICI) used in 94% of cases either alone or combined with docetaxel-based chemotherapy.<br /><br />TTFields usage averaged a median of 12 hours per day (interquartile range 9-16 hours) among patients who used the device for at least one month. Most TTFields prescriptions came from medical oncologists (77%), with treatment taking place predominantly in community hospitals.<br /><br />The real-world uptake of TTFields increased following FDA approval and usage patterns observed align with those from the LUNAR study, particularly the frequent use alongside ICIs. Future research is needed to evaluate further patterns of TTFields use, associated toxicities, and their clinical utility when combined with contemporary systemic treatments for mNSCLC in routine practice.<br /><br />In summary, this initial experience supports growing adoption of TTFields in mNSCLC, especially in combination with immunotherapies, highlighting the need for ongoing data collection to optimize treatment strategies and patient outcomes.

Asset Subtitle

Rupesh Kotecha

Meta Tag

Speaker Rupesh Kotecha

Topic Metastatic Non-small Cell Lung Cancer – Local Therapies

Keywords

Tumor Treating Fields

TTFields

metastatic non-small cell lung cancer

mNSCLC

FDA approval 2024

LUNAR trial

immune checkpoint inhibitors

real-world study

adenocarcinoma

combination therapy